PRIMA: Closure of patent foramen ovale in patients with migraine with aura refractory

It is hypothesized that the presence of a right-left shunt can trigger migraine attacks. The aim of this study was to evaluate whether the closure of a patent foramen ovale may help treat patients with migraine with aura refractory to treatment. A total of 107 patients were included; 53 in the group of foramen ovale closure with Amplatzer PFO Occluder device and 41 in the medical treatment group. At one year there were no differences observed between the two groups in the number of migraine episodes although the group receiving device closure presented a more spaced frequency and lower intensity. 

3_david_smith
David Hildick-Smith
2014-09-17

Original title: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura

More articles by this author

EVERBIO II: Bio-absorbable stent Absorb versus everolimus-eluting or biolimus stents

The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a...

EXCITE ISR: Excimer laser versus balloon angioplasty for stent restenosis of the superficial femoral

This multicenter, prospective, randomized trial compared the Excimer laser atherectomy (Excimer Laser Atherectomy = ELA, Spectranetics, Inc.) with a balloon angioplasty in patients with...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....